Virax biolabs group ltd VRAX.US 總覽分析
VRAX 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足,尚無法提供評分
VRAX 近期報酬表現
-
Virax biolabs group ltd
1.99%
同產業平均
-0.64%
S&P500
與 VRAX 同產業的標的表現
- INM Inmed pharmaceuticals inc價值 2 分趨勢 3 分波段 3 分籌碼 1 分股利 1 分查看更多
VRAX 公司資訊
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.